- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-1/A IPO registration
- 1.1 EX-1.1
- 3.1 EX-3.1
- 3.2 EX-3.2
- 3.3 EX-3.3
- 3.4 EX-3.4
- 3.5 EX-3.5
- 3.6 EX-3.6
- 4.2 EX-4.2
- 4.3 EX-4.3
- 4.4 EX-4.4
- 4.5 EX-4.5
- 4.6 EX-4.6
- 4.8 EX-4.8
- 4.9 EX-4.9
- 4.10 EX-4.10
- 4.11 EX-4.11
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 14.1 EX-14.1
- 16.1 EX-16.1
- 21.1 EX-21.1
- 23.2 EX-23.2
- 23.3 EX-23.3
- EX-FILING FEES Ex-filing Fees
- 22 May 24 424B3 Prospectus supplement
- 8 Apr 24 EFFECT Notice of effectiveness
- 5 Apr 24 POS AM Prospectus update (post-effective amendment)
- 1 Apr 24 POS AM Prospectus update (post-effective amendment)
- 2 Sep 22 424B4 Prospectus supplement with pricing info
- 30 Aug 22 EFFECT Notice of effectiveness
- 18 Aug 22 S-1/A IPO registration (amended)
- 4 Aug 22 S-1/A IPO registration (amended)
- 2 Aug 22 S-1/A IPO registration (amended)
- 27 Jul 22 S-1/A IPO registration (amended)
- 16 Jun 22 S-1/A IPO registration (amended)
- 25 May 22 FWP Free writing prospectus
-
25 May 22 S-1/A IPO registration (amended)
- 25 Apr 22 S-1 IPO registration
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated January 10, 2022, in the Registration Statement (Amendment No. 1 to Form S-1) and related Prospectus of bioAffinity Technologies, Inc. for the registration of shares of its common stock and warrants.
Our report dated January 10, 2022 contains an explanatory paragraph that states the Company has suffered recurring losses from operations and negative cash flows from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/ Ernst & Young LLP
San Antonio, Texas
May 25, 2022